Latuda® (lurasidone HCl) is a once-a-day prescription medicine FDA-approved to treat bipolar depression in adults, children, and teens (10 to 17 years). And, in clinical studies, LATUDA was effective for many people struggling with bipolar depression.
We are creating innovative psychiatric, neurological and respiratory therapies that help transform people's lives, while at the same time we are playing an increasingly active role in the future of global health.
To broadly contribute to society through value creation based on innovative research and development activities for the betterment of health care and fuller lives of people worldwide.
Lead the way to a healthier world.
LATUDA is indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) and monotherapy treatment of adult and pediatric patients (10 to 17 years) with bipolar depression.
The Virtual Education Center is a hub for education and data about bipolar depression. From peer-delivered virtual seminars to in-depth patient profiles and case studies.
The Case Study Challenge delivers an interactive experience and provides an opportunity for you to interact and share insights with your peers on challenging patient cases and their symptoms. Dr. Stephen M. Stahl provides commentary and clinical insights to guide you along the way.
Savings, support, and tools are available for your patients. Get the support they need.
LATUDA is an atypical antipsychotic indicated for the treatment of adult and adolescent patients age 13 to 17 years with schizophrenia. Efficacy was established in adults in five 6-week controlled studies of patients with schizophrenia. In adolescents, efficacy was established in a 6-week study of patients age 13 to 17 years. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
The Montana Psychiatry Conference makes every attempt to provide accurate and timely content available for users. Neither MPC nor third-party content providers are responsible or liable for any such content, including advertising, products or other materials available through third party sites.
The Montana Psychiatry Conference board has decided that due to the recent surge in COVID cases, the hospital situation in Montana, and travel restrictions placed on our speakers by their university-hospital systems, we will be moving the 2021 MPC to a virtual only event.